Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive Disorder [Yahoo! Finance]
Cybin Inc. Common Shares (CYBN)
Company Research
Source: Yahoo! Finance
- Cybin's patent portfolio now includes more than 50 granted patents and over 170 pending applications - - Company expects to commence enrollment for a multinational, multisite Phase 3 program evaluating CYB003 in Major Depressive Disorder around mid-year 2024 - TORONTO, April 16, 2024 BUSINESS WIRE Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (" Cybin " or the " Company "), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced that the United States Patent and Trademark Office has granted U.S. patent 11,958,807 in support of its CYB003 program in Major Depressive Disorder ("MDD"). The patent, which is expected to provide exclusivity until at least 2041, includes claims to pharmaceutical compositions within the Company's proprietary deuterated psilocybin analog program, CYB003. "As we continue to advance CYB003, our deuterated psilocybin
Show less
Read more
Impact Snapshot
Event Time:
CYBN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CYBN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CYBN alerts
High impacting Cybin Inc. Common Shares news events
Weekly update
A roundup of the hottest topics
CYBN
News
- Cybin to Participate at the 27th Annual Milken Institute Global ConferenceBusiness Wire
- Cybin Announces Publication of Research Manuscript in the Journal of Medicinal Chemistry [Yahoo! Finance]Yahoo! Finance
- Cybin Announces Publication of Research Manuscript in the Journal of Medicinal ChemistryBusiness Wire
- Cedar Clinical Research selected as clinical research site for Cybin's Phase 3 Study of CYB003 [Yahoo! Finance]Yahoo! Finance
- Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive DisorderBusiness Wire
CYBN
Sec Filings
- 4/25/24 - Form 6-K
- 4/22/24 - Form D
- 4/18/24 - Form 6-K
- CYBN's page on the SEC website